| |
|
Headlines:
|
 |
Back to index
Gemcitabine - Cisplatin
Abstract: Phase II trial of gemcitabine plus cisplatin in
patients with metastatic urothelial cancer.
PURPOSE: To assess the activity and toxicity of the combination of
gemcitabine and cisplatin in the treatment of chemotherapy-naive patients with
metastatic urothelial cancer. PATIENTS AND METHODS: Forty-six patients with
measurable stage IV carcinoma of the urothelium were enrolled onto this trial.
Gemcitabine 1,000 mg/m(2) was administered intravenously for 30 to 60 minutes on
days 1, 8, and 15 of each 28-day cycle. Cisplatin was administered after
gemcitabine on day 1 of each cycle. The first 11 patients received an initial
cisplatin dose of 100 mg/m(2). Due to the hematologic toxicity observed in
several of these patients, the dose was reduced to 75 mg/m(2) in the remaining
35 patients. Patients were treated with six cycles, unless disease progression
or severe toxicity necessitated earlier discontinuation. RESULTS: Ten of the 46
patients achieved a complete response and nine showed a partial response. The
overall response rate was 41%. The median time to treatment failure was 5.5
months. The median survival was 14.3 months, and the 1-year survival probability
was 54%. Most of the toxicities were hematologic and, in general, easily
manageable. CONCLUSION: Gemcitabine plus cisplatin is active in the treatment of
metastatic urothelial cancer in chemotherapy-naive patients and has an
acceptable clinical safety profile. Studies are under way to further define the
place of gemcitabine in combination with other chemotherapeutic agents in the
treatment of metastatic urothelial cancer.
References
Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol
S, Oh W, Stadler W. Phase II trial of gemcitabine plus cisplatin in patients
with metastatic urothelial cancer. J Clin Oncol 2000 May;18(9):1921-7.

|
|
|
|
Are you a doctor or a nurse?
Do you want to join the Doctors Lounge online medical community?
Participate in editorial activities (publish, peer review, edit) and
give a helping hand to the largest online community of patients.
Click on the link below to see the requirements:
Doctors Lounge Membership
Application |
|
| Regimen |
|
Gemcitabine 1000 mg / M2 IV days 1,
8, 15.
Cisplatin 75 mg / M2 IV day 1.
FREQUENCY....... Repeat cycle every 28 days.N.B. An alternative
scheduling is:
Gemcitabine 1000 mg / M2 IV days 1, 8, 15.
Cisplatin 70 mg / M2 IV day 2.
FREQUENCY....... Repeat cycle every 28 days.
Reference...
Moore et al. J Clin Oncol 1999; 17:2876 - 288. |
|
|
| |
|
|
| |
Summary |
Phase II
gemcitabine - cisplatin in metastatic bladder cancer |
| |
Response Rate |
41% |
| |
Progression Free
Survival |
5.5 months |
| |
Median Survival |
14.3 months |
| |
Toxicity |
manageable
hematologic toxicity |
| |
|
|
|
|